Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Recent updates from the PROMISE study

Annie Cowan • 26 Aug 2022
IMS 2022
Multiple Myeloma

Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, shares some updates from the PROMISE study (NCT03689595), which is screening high-risk individuals for precursor conditions including monoclonal gammopathy of undetermined significance (MGUS) and monoclonal gammopathy of indeterminate potential (MGIP). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

More from Annie Cowan

1:50
Insights into the mechanisms leading to progression from MGUS and SMM to multiple myeloma
Annie Cowan • 26 Aug 2022
3:24
An update on the PANGEA model
Annie Cowan • 26 Aug 2022
1:35
An insight into MGIP and its role in the development of precursor conditions
Annie Cowan • 10 Apr 2022
5:04
The PANGEA model: improving risk stratification in multiple myeloma
Annie Cowan • 10 Apr 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals